




Instance: composition-en-19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: CompositionUvEpi
Title: "Composition for nemdatine Package Leaflet"
Description:  "Composition for nemdatine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp19f088d0c7284b3f1b2eff5965fbb50a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nemdatine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Nemdatine is and what it is used for </li>
<li>What you need to know before you take Nemdatine </li>
<li>How to take Nemdatine </li>
<li>Possible side effects </li>
<li>How to store Nemdatine </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nemdatine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nemdatine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>How does Nemdatine work 
Nemdatine contains the active substance memantine hydrochloride. Nemdatine belongs to a group of 
medicines known as anti-dementia medicines. 
Memory loss in Alzheimer s disease is due to a disturbance of message signals in the brain. The brain 
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve 
signals important in learning and memory. Nemdatine belongs to a group of medicines called NMDA- receptor antagonists. Nemdatine acts on these NMDA-receptors improving the transmission of nerve 
signals and the memory. </p>
<p>What is Nemdatine used for 
Nemdatine is used for the treatment of adult patients with moderate to severe Alzheimer s disease. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Nemdatine 
- if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Nemdatine 
- if you have a history of epileptic seizures 
- if you have recently experienced a myocardial infarction (heart attack), or if you are suffering 
from congestive heart failure or from an uncontrolled hypertension (high blood pressure). </p>
<p>In these situations the treatment should be carefully supervised, and the clinical benefit of Nemdatine 
reassessed by your doctor on a regular basis. 
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your 
kidney function and if necessary adapt the memantine doses accordingly. </p>
<p>The use of medicinal products called amantadine (for the treatment of Parkinson s disease), ketamine 
(a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and 
other NMDA-antagonists at the same time should be avoided. </p>
<p>Children and adolescents 
Nemdatine is not recommended for children and adolescents under the age of 18 years. </p>
<p>Other medicines and Nemdatine 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, Nemdatine may change the effects of the following medicines and their dose may need to 
be adjusted by your doctor:</p>
<ul>
<li>amantadine, ketamine, dextromethorphan </li>
<li>dantrolene, baclofen </li>
<li>cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine </li>
<li>hydrochlorothiazide (or any combination with hydrochlorothiazide) </li>
<li>anticholinergics (substances generally used to treat movement disorders or intestinal cramps) </li>
<li>anticonvulsants (substances used to prevent and relieve seizures) </li>
<li>barbiturates (substances generally used to induce sleep) </li>
<li>dopaminergic agonists (substances such as L-dopa, bromocriptine) </li>
<li>neuroleptics (substances used in the treatment of mental disorders) </li>
<li>oral anticoagulants </li>
</ul>
<p>If you go into hospital, let your doctor know that you are taking Nemdatine. </p>
<p>Nemdatine with food and drink 
You should inform your doctor if you have recently changed or intend to change your diet 
substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal 
tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction 
(poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your 
doctor may need to adjust the dose of your medicine. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy 
The use of memantine in pregnant women is not recommended. </p>
<p>Breast-feeding 
Women taking Nemdatine should not breast-feed. </p>
<p>Driving and using machines 
Your doctor will tell you whether your illness allows you to drive and to use machines safely. Also, 
Nemdatine may change your reactivity, making driving or operating machinery inappropriate. </p>
<p>Nemdatine contains lactose monohydrate 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicinal product. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Dosage 
The recommended dose of Nemdatine for adults and older people is 20 mg once a day. 
In order to reduce the risk of side effects this dose is achieved gradually by the following daily 
treatment scheme: </p>
<p>Week 1 
One 5 mg tablet 
Week 2 
Two 5 mg tablets 
Week 3 
Three 5 mg tablets 
Week 4 and beyond 
Four 5 mg tablets once a day </p>
<p>The usual starting dose is one tablet once a day (1x 5 mg) for the first week. This is increased to two 
tablets once a day (1x 10 mg) in the second week and to three tablets once a day (1x 15 mg) in the 
third week. From the fourth week on, the usual dose is 4 tablets once a day (1x 20 mg). </p>
<p>Dosage in patients with impaired kidney function 
If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In 
this case, monitoring of your kidney function should be performed by your doctor at specified 
intervals. </p>
<p>Administration 
Nemdatine should be administered orally once a day. To benefit from your medicine you should take it 
regularly every day at the same time of the day. The tablets should be swallowed with some water. 
The tablets can be taken with or without food. </p>
<p>Duration of treatment<br />
Continue to take Nemdatine as long as it is of benefit to you. Your doctor should assess your treatment 
on a regular basis. </p>
<p>If you take more Nemdatine than you should 
- In general, taking too much Nemdatine should not result in any harm to you. You may 
experience increased symptoms as described in section 4  Possible side effects . 
- If you take a large overdose of Nemdatine, contact your doctor or get medical advice, as you 
may need medical attention. </p>
<p>If you forget to take Nemdatine 
- If you find you have forgotten to take your dose of Nemdatine, wait and take your next dose at 
the usual time. 
- Do not take a double dose to make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>In general, the observed side effects are mild to moderate. </p>
<p>Common (affects 1 to 10 users in 100) 
- Headache, sleepiness, constipation, elevated liver function test, dizziness, balance disorders, 
shortness of breath, high blood pressure and drug hypersensitivity </p>
<p>Uncommon (affects 1 to 10 users in 1,000) 
- Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure 
and venous blood clotting (thrombosis/thromboembolism) </p>
<p>Very Rare (affects less than 1 user in 10,000) 
- Seizures 
Not known (frequency cannot be estimated from the available data) 
- Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions </p>
<p>Alzheimer s disease has been associated with depression, suicidal ideation and suicide. These events 
have been reported in patients treated with memantine. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>Do not store above 25 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nemdatine contains 
- The active substance is memantine hydrochloride. Each film-coated tablet contains 5 mg 
memantine hydrochloride equivalent to 4.15 mg memantine. </p>
<ul>
<li>The other ingredients are: Tablet core: Microcrystalline cellulose, crospovidone Type A, talc 
and magnesium stearate. Tablet coat (Opadry II White 33G28435): Hypromellose 6cP, titanium 
dioxide (E171), lactose monohydrate, macrogol 3350 and triacetin. </li>
</ul>
<p>What Nemdatine looks like and contents of the pack 
Nemdatine 5 mg film-coated tablets (tablets) are white, oval shaped, biconvex, 8 mm x 4.5 mm in size, 
with the marking  M5  engraved on one side. </p>
<p>Pack sizes 
Blister packs: 42 and 98 film-coated tablets.  </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Actavis Group PTC ehf. 
Dalshraun 1 
220 Hafnarfj r ur 
Iceland </p>
<p>Manufacturer 
Actavis Ltd. 
BLB 015-016 Bulebel Industrial Estate 
Zejtun ZTN 3Malta 
TEVA Gy gyszergy r Zrt. 
Pallagi  t Debrecen 4Hungary </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>: +359 24899Luxembourg/Luxemburg 
ratiopharm GmbH 
Allemagne/Deutschland 
T l/Tel: +49 73140 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
ratiopharm GmbH 
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
TEVA HELLAS A.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Teva Pharma, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
Teva Pharma - Produtos Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Teva Pharma Iceland ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l. 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
TEVA HELLAS A.E. </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij<br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Accord Healthcare Ireland Ltd. 
Ireland 
Tel: +353 214619This leaflet was last revised in {MM/YYYY} </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: CompositionUvEpi
Title: "Composition for nemdatine Package Leaflet"
Description:  "Composition for nemdatine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp19f088d0c7284b3f1b2eff5965fbb50a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nemdatine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Nemdatine 
3. Sådan skal De tage Nemdatine 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nemdatine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nemdatine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvordan virker Nemdatine 
Nemdatine indeholder det aktive stof memantinhydrochlorid. Det tilhører gruppen af medicin kaldet 
antidemensmedicin (medicin til behandling af demens). 
Hukommelsestab ved Alzheimers sygdom skyldes en forstyrrelse af signalstoffer i hjernen. Hjernen 
indeholder såkaldte N-methyl-D-aspartat (NMDA)-receptorer, der er involveret i overførslen af 
nervesignaler, som er vigtige for indlæring og hukommelse. Nemdatine hører til en gruppe af 
lægemidler kaldet NMDA-receptor-antagonister. Nemdatine indvirker på disse NMDA-receptorer og 
forbedrer overførslen af nervesignaler samt hukommelsen. </p>
<p>Hvad anvendes Nemdatine til? 
Nemdatine anvendes til behandling af voksne patienter med moderat til svær Alzheimers sygdom. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Nemdatine 
- hvis De er allergisk over for memantinhydrochlorid eller et af de øvrige indholdsstoffer i 
Nemdatine filmovertrukne tabletter (angivet i pkt. 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Nemdatine 
- hvis De tidligere har haft epileptiske anfald 
- hvis De for nylig har haft blodprop i hjertet (myokardieinfarkt), eller hvis De lider af dårligt 
hjerte eller ukontrolleret forhøjet blodtryk (hypertension) </p>
<p>I disse situationer bør behandlingen overvåges nøje, og den kliniske gavn af Nemdatine skal 
regelmæssigt vurderes af Deres læge. 
Hvis De har nedsat nyrefunktion (nyreproblemer), bør Deres læge nøje overvåge Deres nyrefunktion 
og om nødvendigt tilpasse memantin-dosen derefter. </p>
<p>Samtidig brug af lægemidler ved navn amantadin (til behandling af Parkinsons sygdom), ketamin (et 
middel, der anvendes til bedøvelse), dextromethorfan (anvendes generelt til behandling af hoste) og 
andre NMDA-antagonister bør undgås. </p>
<p>Børn og unge 
Nemdatine anbefales ikke til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Nemdatine 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin. Dette gælder også medicin, som ikke er købt 
på recept. </p>
<p>I særdeleshed kan Nemdatine ændre virkningen af følgende lægemidler, og lægen kan derfor være 
nødt til at ændre doseringen:</p>
<ul>
<li>amantadin, ketamin, dextromethorfan </li>
<li>dantrolen, baklofen </li>
<li>cimetidin, ranitidin, procainamid, quinidin, quinin, nikotin </li>
<li>hydrochlorothiazid (eller en hvilken som helst kombination med hydrochlorothiazid) </li>
<li>antikolinergika (stoffer, der generelt bruges til behandling af lidelser i bevægeapparatet eller 
tarmkramper) </li>
<li>antikonvulsiva (stoffer, der bruges til at forebygge og afhjælpe krampeanfald) </li>
<li>barbiturater (stoffer, der generelt bruges som sovemidler) </li>
<li>dopaminerge agonister (stoffer såsom L-dopa, bromokriptin) </li>
<li>neuroleptika (stoffer, der bruges til behandling af sindslidelser) </li>
<li>orale antikoagulantia </li>
</ul>
<p>Hvis De kommer på hospitalet, skal De sige til lægen, at De får Nemdatine. </p>
<p>Brug af Nemdatine sammen med mad og drikke 
De bør informere Deres læge, hvis De for nylig har ændret eller har i sinde at ændre Deres kost 
væsentligt (f.eks. fra en normal kost til en streng vegetarisk kost). De bør også informere Deres læge, 
hvis De lider af tilstande med renal tubulær acidose (RTA, overskud af syredannende stoffer i blodet 
på grund af nedsat nyrefunktion) eller alvorlige infektioner i urinvejene (som urinen udskilles 
igennem). Deres læge kan i så fald være nødt til at justere Deres medicindosis. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Graviditet 
Memantin anbefales ikke til gravide kvinder. </p>
<p>Amning 
Kvinder, der tager Nemdatine, bør ikke amme. </p>
<p>Trafik- og arbejdssikkerhed 
Deres læge vil fortælle Dem, om Deres sygdom tillader, at De uden risiko kan køre bil eller 
motorcykel, og om De kan cykle eller arbejde med værktøj og maskiner. Nemdatine kan måske også 
påvirke Deres reaktionsevne, så det ikke er hensigtsmæssigt at køre bil, motorcykel eller cykel eller 
arbejde med værktøj og maskiner. </p>
<p>Nemdatine indeholder laktosemonohydrat 
Hvis Deres læge har fortalt Dem, at De ikke tåler visse sukkerarter, skal De kontakte Deres læge, før 
De tager dette lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Nemdatine nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Dosering 
Den anbefalede dosis af Nemdatine til voksne og til ældre personer er 20 mg én gang dagligt. 
For at mindske risikoen for bivirkninger opnås denne dosis gradvist ud fra følgende daglige 
behandlingsskema: </p>
<ol>
<li>uge 
En tablet à 5 mg </li>
<li>uge 
To tabletter à 5 mg </li>
<li>uge 
Tre tabletter à 5 mg </li>
<li>uge og derefter 
Fire tabletter à 5 mg én gang 
dagligt </li>
</ol>
<p>Den normale startdosis er en tablet én gang dagligt (1 x 5 mg) i den første uge. Denne øges til to 
tabletter en gang dagligt (1 x 10 mg) i den anden uge og til tre tabletter en gang dagligt (1x 15 mg) i 
den tredje uge. Fra og med den fjerde uge er den normale dosis 4 tabletter en gang dagligt (1 x 20 mg). </p>
<p>Dosis til patienter med nedsat nyrefunktion 
Hvis De har nedsat nyrefunktion, afgør Deres læge, hvilken dosis der passer til Deres tilstand. I så fald 
bør Deres læge overvåge Deres nyrefunktion regelmæssigt. </p>
<p>Administration 
Nemdatine bør indtages gennem munden en gang pr. dag. De bør tage tabletterne regelmæssigt hver 
dag på samme tidspunkt af dagen for at opnå størst mulig virkning af tabletterne. Tabletterne bør 
synkes sammen med noget vand. Tabletterne kan indtages uafhængigt af måltider. </p>
<p>Behandlingens varighed 
Bliv ved med at tage Nemdatine, så længe De har gavn af det. Deres læge bør regelmæssigt vurdere 
Deres behandling. </p>
<p>Hvis De har taget for meget Nemdatine 
- Generelt burde indtagelse af for meget Nemdatine ikke være skadeligt for Dem. De kan opleve 
forøgede symptomer, som beskrevet i punkt 4 “Bivirkninger". 
- Hvis De tager en stor overdosis af Nemdatine, skal De søge læge, da De kan have behov for 
medicinsk behandling. </p>
<p>Hvis De har glemt at tage Nemdatine 
- Hvis De har glemt at tage Deres dosis af Nemdatine, skal De vente og tage Deres næste dosis på 
det sædvanlige tidspunkt. 
- De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>De bivirkninger, der er set, er generelt milde til moderate. </p>
<p>Almindelige (påvirker 1-10 ud af 100 patienter) 
- Hovedpine, søvnighed, forstoppelse, forhøjede værdier ved leverfunktionsprøver, svimmelhed, 
balanceforstyrrelser, kortåndethed, forhøjet blodtryk og overfølsomhed over for medicinen </p>
<p>Ikke almindelige (påvirker 1-10 ud af 1.000 patienter) 
- Træthed, svampeinfektioner, forvirring, hallucinationer, opkastning, unormal gang, hjertesvigt 
og blodprop i en blodåre (vene) </p>
<p>Meget sjældne (påvirker færre end 1 ud af 10.000 patienter) 
- Krampeanfald </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data) 
- Betændelse i bugspytkirtlen, leverbetændelse (hepatitis) og psykotiske reaktioner </p>
<p>Alzheimers sygdom er blevet sat i forbindelse med depression, selvmordstanker og selvmord. Disse 
hændelser er blevet beskrevet hos patienter i behandling med memantin. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, apotekspersonalet eller sygeplejersken. 
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nemdatine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nemdatine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke Nemdatine efter den udløbsdato, der står på æsken og blisteret efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25 °C. </p>
<p>Spørg apotekspersonalet, hvordan De skal aflevere medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.   </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Nemdatine indeholder:</p>
<ul>
<li>
<p>Aktivt stof: memantinhydrochlorid. Hver filmovertrukket tablet indeholder 5 mg 
memantinhydrochlorid svarende til 4,15 mg memantin. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: Tabletkerne: Mikrokrystallinsk cellulose, crospovidon type A, talkum 
og magnesiumstearat. Tabletovertræk (Opadry II White 33G28435): Hypromellose 6cP, 
titandioxid (E171), laktosemonohydrat, macrogol 3350 og triacetin. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Nemdatine 5 mg filmovertrukne tabletter (tabletter) er hvide, ovale, bikonvekse, har en størrelse på 
8 mm x 4,5 mm og er præget med “M5" på den ene side. </p>
<p>Pakningsstørrelser 
Blisterpakker: 42 og 98 filmovertrukne tabletter.  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Actavis Group PTC ehf. 
Dalshraun 1 
220 Hafnarfjörður 
Island </p>
<p>Fremstiller 
Actavis Ltd. 
BLB 015-016 Bulebel Industrial Estate 
Zejtun ZTN 3Malta </p>
<p>TEVA Gyógyszergyár Zrt. 
Pallagi út Debrecen 4Ungarn </p>
<p>Hvis De ønsker yderligere oplysninger om Nemdatine, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
Tél/Tel: +32 38207 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Тел: +359 24899 
Luxembourg/Luxemburg 
ratiopharm GmbH 
Allemagne/Deutschland 
Tél/Tel: +49 73140 
Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 
Deutschland 
ratiopharm GmbH 
Tel: +49 73140 
Nederland 
Teva Nederland B.V. 
Tel: +31 8000228 
Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610 
Norge 
Teva Norway AS 
Tlf: +47 66775 
Ελλάδα 
TEVA HELLAS A.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Teva Pharma, S.L.U. 
Tel: +34 913873 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Teva Santé 
Tél: +33 155917 
Portugal 
Teva Pharma - Produtos Farmacêuticos, Lda. 
Tel: +351 214767 
Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Teva Pharma Iceland ehf. 
Sími: +354 5503 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Teva Italia S.r.l. 
Tel: +39 028917 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
TEVA HELLAS A.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā 
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Accord Healthcare Ireland Ltd. 
Ireland 
Tel: +353 214619 </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om Nemdatine på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu /. 
Indlægsseddel: Information til brugeren </p>
<p>Nemdatine 10 mg filmovertrukne tabletter 
memantinhydrochlorid </p>
<p>Læs denne indlægsseddel grundigt, inden De begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. De kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, De vil vide. 
- Lægen har ordineret lægemidlet til Dem personligt. Lad derfor være med at give det til andre. 
Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. 
- Tal med lægen eller apotekspersonalet, hvis De får bivirkninger. Dette omfatter bivirkninger, 
som ikke er nævnt i denne indlægsseddel. Se afsnit 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nemdatine Package Leaflet for language en"
Description: "ePI document Bundle for nemdatine Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-19f088d0c7284b3f1b2eff5965fbb50a"
* entry[0].resource = composition-en-19f088d0c7284b3f1b2eff5965fbb50a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp19f088d0c7284b3f1b2eff5965fbb50a"
* entry[=].resource = mp19f088d0c7284b3f1b2eff5965fbb50a
                            
                    
Instance: bundlepackageleaflet-da-19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nemdatine Package Leaflet for language da"
Description: "ePI document Bundle for nemdatine Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-19f088d0c7284b3f1b2eff5965fbb50a"
* entry[0].resource = composition-da-19f088d0c7284b3f1b2eff5965fbb50a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp19f088d0c7284b3f1b2eff5965fbb50a"
* entry[=].resource = mp19f088d0c7284b3f1b2eff5965fbb50a
                            
                    



Instance: mp19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Nemdatine 5 mg film-coated tablets"
Description: "Nemdatine 5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/824/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Nemdatine 5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 19f088d0c7284b3f1b2eff5965fbb50aListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "nemdatine"

* status = #current
* mode = #working

* title = "List of all ePIs associated with nemdatine"

* subject = Reference(mp19f088d0c7284b3f1b2eff5965fbb50a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#nemdatine "nemdatine"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-19f088d0c7284b3f1b2eff5965fbb50a) // nemdatine en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-19f088d0c7284b3f1b2eff5965fbb50a) // nemdatine da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-19f088d0c7284b3f1b2eff5965fbb50a
InstanceOf: List

* insert 19f088d0c7284b3f1b2eff5965fbb50aListRuleset
    